All publications of “Pui San Tan”

1 results

Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer

Pedro Nazareth Aguiar Jr. ORCID logo , Pui San Tan ORCID logo , Sarah Simko ORCID logo , Carmelia Maria Noia Barreto ORCID logo , Bárbara de Souza Gutierres ORCID logo , Auro del Giglio ORCID logo , [...]

DOI: 10.31744/einstein_journal/2019GS4414

ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted […]